Realta Investment Advisors Sells 3,184 Shares of Eli Lilly and Company (NYSE:LLY)

Realta Investment Advisors trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 74.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,114 shares of the company’s stock after selling 3,184 shares during the period. Realta Investment Advisors’ holdings in Eli Lilly and Company were worth $1,036,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Key Financial Inc raised its holdings in shares of Eli Lilly and Company by 1.5% in the third quarter. Key Financial Inc now owns 883 shares of the company’s stock worth $782,000 after buying an additional 13 shares during the period. Greenwich Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 18.2% in the third quarter. Greenwich Wealth Management LLC now owns 2,847 shares of the company’s stock worth $2,522,000 after buying an additional 439 shares during the period. Invesco LLC raised its holdings in shares of Eli Lilly and Company by 0.4% in the third quarter. Invesco LLC now owns 5,205 shares of the company’s stock worth $4,611,000 after buying an additional 22 shares during the period. AM Investment Strategies LLC raised its holdings in shares of Eli Lilly and Company by 9.1% in the third quarter. AM Investment Strategies LLC now owns 371 shares of the company’s stock worth $328,000 after buying an additional 31 shares during the period. Finally, Farther Finance Advisors LLC raised its holdings in shares of Eli Lilly and Company by 12.2% in the third quarter. Farther Finance Advisors LLC now owns 13,973 shares of the company’s stock worth $12,379,000 after buying an additional 1,520 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Down 1.3 %

Shares of NYSE LLY opened at $818.93 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $777.43 billion, a PE ratio of 88.53, a price-to-earnings-growth ratio of 3.13 and a beta of 0.43. The stock’s fifty day simple moving average is $911.04 and its two-hundred day simple moving average is $866.16. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 EPS. As a group, analysts expect that Eli Lilly and Company will post 13.23 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.63%. Eli Lilly and Company’s payout ratio is 56.22%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on LLY shares. Bank of America reduced their price target on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a report on Thursday. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Berenberg Bank raised their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Truist Financial raised their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a report on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,009.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.